{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.2","upperLimit":"94.2","value":"90.1"},{"groupId":"OG001","lowerLimit":"87.6","upperLimit":"97.0","value":"93.9"},{"groupId":"OG002","lowerLimit":"81.6","upperLimit":"93.4","value":"88.9"},{"groupId":"OG003","lowerLimit":"77.3","upperLimit":"90.3","value":"85.1"}]}],"title":"24 Months (n=124,123,124,127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.2","upperLimit":"92.3","value":"87.5"},{"groupId":"OG001","lowerLimit":"75.6","upperLimit":"89.5","value":"83.8"},{"groupId":"OG002","lowerLimit":"75.3","upperLimit":"89.1","value":"83.5"},{"groupId":"OG003","lowerLimit":"67.7","upperLimit":"83.1","value":"76.5"}]}],"title":"36 Months (n=124,123,124,127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.3","upperLimit":"85.9","value":"79.7"},{"groupId":"OG001","lowerLimit":"73.4","upperLimit":"88.0","value":"82.0"},{"groupId":"OG002","lowerLimit":"72.1","upperLimit":"86.9","value":"80.7"},{"groupId":"OG003","lowerLimit":"61.9","upperLimit":"78.4","value":"71.1"}]}],"title":"48 Months (n=124,123,124,127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.1","upperLimit":"82.0","value":"75.1"},{"groupId":"OG001","lowerLimit":"68.9","upperLimit":"84.7","value":"78.0"},{"groupId":"OG002","lowerLimit":"64.1","upperLimit":"80.9","value":"73.6"},{"groupId":"OG003","lowerLimit":"59.8","upperLimit":"76.7","value":"69.1"}]}],"title":"60 Months (n=124,123,124,127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.3","upperLimit":"75.8","value":"67.9"},{"groupId":"OG001","lowerLimit":"62.9","upperLimit":"80.1","value":"72.6"},{"groupId":"OG002","lowerLimit":"61.8","upperLimit":"79.0","value":"71.4"},{"groupId":"OG003","lowerLimit":"57.6","upperLimit":"74.9","value":"67.1"}]}],"title":"72 Months (n=124,123,124,127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.6","upperLimit":"71.0","value":"62.6"},{"groupId":"OG001","lowerLimit":"58.0","upperLimit":"76.2","value":"68.1"},{"groupId":"OG002","lowerLimit":"57.9","upperLimit":"76.0","value":"67.9"},{"groupId":"OG003","lowerLimit":"55.3","upperLimit":"73.0","value":"65.0"}]}],"title":"84 Months (n=124,123,124,127)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"124"},{"groupId":"OG003","value":"126"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-resistant participants were summarized.","reportingStatus":"POSTED","timeFrame":"24, 36, 48, 60, 72, and 84 months","title":"Percent of Imatinib-Resistant Participants With Overall Survival (OS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}